Amarin Corp Ads (AMRN) 1.53 $AMRN
Amarin Reaches Target Enrollment in Cardiovascular Outcomes Study of Vascepa(R) in Patients With Elevated Triglycerides Despite Statin Therapy
Marketwired - Thu Mar 31, 6:01AM CDT
Amarin Corporation plc (NASDAQ: AMRN) today announced that target patient enrollment has been reached in its REDUCE-IT cardiovascular outcomes trial of Vascepa (icosapent ethyl). Amarin also announced that the onset of approximately 60% of the target aggregate number of primary cardiovascular events within the REDUCE-IT study has triggered preparation for a pre-specified interim efficacy and safety analysis by the independent Data Monitoring Committee (DMC). Amarin currently expects the independent interim analysis to be conducted in approximately six months.
AMRN: 1.53 (+0.03)
7 Top Stocks to Buy in March
Steve Symington, Dan Caplinger, Jason Hall, Daniel Miller, Andrés Cardenal, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Tue Mar 15, 5:00PM CDT
After suffering through a historically bad start to the year through the first half of February, patient equities investors have since been treated to a modest rebound. The S&P 500, Nasdaq Composite, and Dow Jones Industrial Average have each...
LNKD: 114.35 (+0.52), CMG: 470.97 (+4.82), AMRN: 1.53 (+0.03), TREX: 47.93 (+0.50), PYPL: 38.60 (-0.44), INTU: 104.01 (+0.83), TWX: 72.55 (+0.39)
Court Approves Proposed Settlement Terms in Amarin First Amendment Litigation
Marketwired - Wed Mar 09, 11:31AM CST
Amarin Corporation plc (NASDAQ: AMRN) announced today that the Honorable Judge Paul A. Engelmayer of the United States District Court for the Southern District of New York has approved the settlement terms proposed by the parties related to the Amarin First Amendment litigation (Amarin Pharma, Inc. et al. v. FDA et al., No. 15-3588 (S.D.N.Y. May 7, 2015)) and disclosed in Amarin's press release dated March 8, 2016. The Court has entered a final order of approval reflecting these terms and concluding the underlying litigation.
AMRN: 1.53 (+0.03)
FDA settles with drugmaker in fish-oil drug marketing case
By MATTHEW PERRONE - AP - Tue Mar 08, 5:26PM CST
WASHINGTON (AP) — The maker of a prescription fish-oil drug says it has reached a legal settlement that will allow it to promote unapproved uses of its drug for lowering fat levels.
AMRN: 1.53 (+0.03)
Amarin's Right to Promote Vascepa(R) Off-Label Affirmed Under First Amendment Litigation Settlement Terms
Marketwired - Tue Mar 08, 3:13PM CST
Amarin Corporation plc (NASDAQ: AMRN) announced today settlement terms have been reached among the parties to resolve the Amarin First Amendment litigation (Amarin Pharma, Inc. et al. v. FDA et al., No. 15-3588 (S.D.N.Y. May 7, 2015)). Under the terms, the U.S. Food and Drug Administration (FDA) and the U.S. government have agreed to be bound by the August 7, 2015, judicial declaration that Amarin may engage in truthful and non-misleading speech promoting the off-label use of Vascepa® (icosapent ethyl) Capsules. Amarin's expanded promotion of Vascepa, initiated following the August 2015 judicial declaration, continues as planned.
AMRN: 1.53 (+0.03)
Amarin Appoints Craig B. Granowitz Chief Medical Officer and Names Steven Ketchum Chief Scientific Officer
Marketwired - Thu Jan 21, 6:56AM CST
Amarin Corporation plc (NASDAQ: AMRN) has appointed Craig B. Granowitz, M.D., Ph.D. to the position of chief medical officer. In this role, Dr. Granowitz will provide strategic and operational leadership across multiple functions including medical affairs, drug safety and medical communications. In addition, the title and role of Steven Ketchum, Ph.D., Amarin's president of research and development and senior vice president, has been expanded to include the responsibility of chief scientific officer.
AMRN: 1.53 (+0.03)
3 Reasons Behind Amarin's Strong 2015
George Budwell, The Motley Fool - Motley Fool - Wed Jan 13, 11:02AM CST
What : Shares of the small-cap biopharma Amarin Corp. gained nearly 70% in 2015, according to data provided by S&P Capital IQ . The Irish drugmaker's strong rebound from an abysmal 2014 was the result of three positive catalysts unfolding for...
AMRN: 1.53 (+0.03)
Healthcare Sector Equities under Review -- Amarin, Arrowhead Research, Zogenix, and PetMed Express
ACCESSWIRE - Wed Jan 13, 7:02AM CST
NEW YORK, NY / ACCESSWIRE / January 13, 2016 / Park Lane Advisor has initiated coverage on the following equities: Amarin Corporation PLC (NASDAQ: AMRN), Arrowhead Research Corporation (NASDAQ: ARWR), Zogenix Inc. (NASDAQ: ZGNX), and PetMed Express Inc. (NASDAQ: PETS). Free research report on Amarin can be accessed at http://www.parklaneadvisor.com/ On Tuesday, January 12, 2016, the NASDAQ Composite ended at 4,685.92, up 1.03%, the Dow Jones Industrial Average advanced 0.72%, to finish the day at 16,516.22, and the S&P 500 closed at 1,938.68, up 0.78%. The gains were broad based as six out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
PETS: 17.91 (-0.03), ARWR: 4.82 (+0.08), ZGNX: 9.24 (-0.07), AMRN: 1.53 (+0.03)
Amarin Reports Preliminary 2015 Net Product Sales and Provides 2016 Revenue and Business Outlook
Marketwired - Mon Jan 11, 6:01AM CST
Amarin Corporation plc (NASDAQ: AMRN), today provided a business update, including preliminary unaudited fourth quarter and full year 2015 revenue and 2016 revenue outlook. Amarin plans to discuss these results and expectations for the coming year with investors in conjunction with the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, California.
JPM: 59.22 (-0.49), AMRN: 1.53 (+0.03)
Healthcare Sector Equities under the Scanner -- Zogenix, Amarin, SciClone Pharma, and PetMed Express
ACCESSWIRE - Fri Dec 18, 7:03AM CST
NEW YORK, NY / ACCESSWIRE / December 18, 2015 / Park Lane Advisor has initiated coverage on the following equities: Zogenix Inc. (NASDAQ: ZGNX), Amarin Corporation PLC (NASDAQ: AMRN), SciClone Pharmaceuticals Inc. (NASDAQ: SCLN), and PetMed Express Inc. (NASDAQ: PETS). Free research report on Zogenix can be accessed at http://www.parklaneadvisor.com/ On Thursday, December 17, 2015, the NASDAQ Composite ended at 5,002.55, down 1.35%, the Dow Jones Industrial Average declined 1.43%, to finish the day at 17,495.84, and the S&P 500 closed at 2,041.89, down 1.50%. The losses were broad based as eight out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
PETS: 17.91 (-0.03), ZGNX: 9.24 (-0.07), AMRN: 1.53 (+0.03), SCLN: 11.00 (+1.33)
Amarin Added to NASDAQ Biotechnology Index
Marketwire Canada - Mon Dec 14, 5:06AM CST
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced that it has been selected for addition to the NASDAQ Biotechnology Index effective December 21, 2015.
AMRN: 1.53 (+0.03)
Market Data on Movers and Shakers - Research on Medifast, Potbelly, Amarin and Idera Pharmaceuticals
ACCESSWIRE - Fri Dec 04, 8:00AM CST
NEW YORK, NY / ACCESSWIRE / December 4, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Medifast Inc (NYSE: MED), Potbelly Corp (NASDAQ: PBPB), Amarin Corporation plc (NASDAQ: AMRN) and Idera Pharmaceuticals Inc (NASDAQ: IDRA). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
IDRA: 1.98 (+0.05), MED: 30.19 (+0.21), AMRN: 1.53 (+0.03), PBPB: 13.61 (-0.12)
Amarin to Present at the Oppenheimer & Co. Inc. 26th Annual Healthcare Conference
Marketwired - Wed Dec 02, 5:01AM CST
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's President and Chief Executive Officer, is scheduled to present a general company update at the Oppenheimer & Co. Inc. 26th Annual Healthcare Conference in New York City on Wednesday, December 9, 2015, at 9:10 a.m. ET.
AMRN: 1.53 (+0.03)
Amarin Reaches Target Enrollment in Cardiovascular Outcomes Study of Vascepa(R) in Patients With Elevated Triglycerides Despite Statin Therapy
Marketwired - Thu Mar 31, 6:01AM CDT
Amarin Corporation plc (NASDAQ: AMRN) today announced that target patient enrollment has been reached in its REDUCE-IT cardiovascular outcomes trial of Vascepa (icosapent ethyl). Amarin also announced that the onset of approximately 60% of the target aggregate number of primary cardiovascular events within the REDUCE-IT study has triggered preparation for a pre-specified interim efficacy and safety analysis by the independent Data Monitoring Committee (DMC). Amarin currently expects the independent interim analysis to be conducted in approximately six months.
AMRN: 1.53 (+0.03)
7 Top Stocks to Buy in March
Steve Symington, Dan Caplinger, Jason Hall, Daniel Miller, Andrés Cardenal, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Tue Mar 15, 5:00PM CDT
After suffering through a historically bad start to the year through the first half of February, patient equities investors have since been treated to a modest rebound. The S&P 500, Nasdaq Composite, and Dow Jones Industrial Average have each...
LNKD: 114.35 (+0.52), CMG: 470.97 (+4.82), AMRN: 1.53 (+0.03), TREX: 47.93 (+0.50), PYPL: 38.60 (-0.44), INTU: 104.01 (+0.83), TWX: 72.55 (+0.39)
Court Approves Proposed Settlement Terms in Amarin First Amendment Litigation
Marketwired - Wed Mar 09, 11:31AM CST
Amarin Corporation plc (NASDAQ: AMRN) announced today that the Honorable Judge Paul A. Engelmayer of the United States District Court for the Southern District of New York has approved the settlement terms proposed by the parties related to the Amarin First Amendment litigation (Amarin Pharma, Inc. et al. v. FDA et al., No. 15-3588 (S.D.N.Y. May 7, 2015)) and disclosed in Amarin's press release dated March 8, 2016. The Court has entered a final order of approval reflecting these terms and concluding the underlying litigation.
AMRN: 1.53 (+0.03)
FDA settles with drugmaker in fish-oil drug marketing case
By MATTHEW PERRONE - AP - Tue Mar 08, 5:26PM CST
WASHINGTON (AP) — The maker of a prescription fish-oil drug says it has reached a legal settlement that will allow it to promote unapproved uses of its drug for lowering fat levels.
AMRN: 1.53 (+0.03)
Amarin's Right to Promote Vascepa(R) Off-Label Affirmed Under First Amendment Litigation Settlement Terms
Marketwired - Tue Mar 08, 3:13PM CST
Amarin Corporation plc (NASDAQ: AMRN) announced today settlement terms have been reached among the parties to resolve the Amarin First Amendment litigation (Amarin Pharma, Inc. et al. v. FDA et al., No. 15-3588 (S.D.N.Y. May 7, 2015)). Under the terms, the U.S. Food and Drug Administration (FDA) and the U.S. government have agreed to be bound by the August 7, 2015, judicial declaration that Amarin may engage in truthful and non-misleading speech promoting the off-label use of Vascepa® (icosapent ethyl) Capsules. Amarin's expanded promotion of Vascepa, initiated following the August 2015 judicial declaration, continues as planned.
AMRN: 1.53 (+0.03)
Amarin Appoints Craig B. Granowitz Chief Medical Officer and Names Steven Ketchum Chief Scientific Officer
Marketwired - Thu Jan 21, 6:56AM CST
Amarin Corporation plc (NASDAQ: AMRN) has appointed Craig B. Granowitz, M.D., Ph.D. to the position of chief medical officer. In this role, Dr. Granowitz will provide strategic and operational leadership across multiple functions including medical affairs, drug safety and medical communications. In addition, the title and role of Steven Ketchum, Ph.D., Amarin's president of research and development and senior vice president, has been expanded to include the responsibility of chief scientific officer.
AMRN: 1.53 (+0.03)
3 Reasons Behind Amarin's Strong 2015
George Budwell, The Motley Fool - Motley Fool - Wed Jan 13, 11:02AM CST
What : Shares of the small-cap biopharma Amarin Corp. gained nearly 70% in 2015, according to data provided by S&P Capital IQ . The Irish drugmaker's strong rebound from an abysmal 2014 was the result of three positive catalysts unfolding for...
AMRN: 1.53 (+0.03)
Healthcare Sector Equities under Review -- Amarin, Arrowhead Research, Zogenix, and PetMed Express
ACCESSWIRE - Wed Jan 13, 7:02AM CST
NEW YORK, NY / ACCESSWIRE / January 13, 2016 / Park Lane Advisor has initiated coverage on the following equities: Amarin Corporation PLC (NASDAQ: AMRN), Arrowhead Research Corporation (NASDAQ: ARWR), Zogenix Inc. (NASDAQ: ZGNX), and PetMed Express Inc. (NASDAQ: PETS). Free research report on Amarin can be accessed at http://www.parklaneadvisor.com/ On Tuesday, January 12, 2016, the NASDAQ Composite ended at 4,685.92, up 1.03%, the Dow Jones Industrial Average advanced 0.72%, to finish the day at 16,516.22, and the S&P 500 closed at 1,938.68, up 0.78%. The gains were broad based as six out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
PETS: 17.91 (-0.03), ARWR: 4.82 (+0.08), ZGNX: 9.24 (-0.07), AMRN: 1.53 (+0.03)
Amarin Reports Preliminary 2015 Net Product Sales and Provides 2016 Revenue and Business Outlook
Marketwired - Mon Jan 11, 6:01AM CST
Amarin Corporation plc (NASDAQ: AMRN), today provided a business update, including preliminary unaudited fourth quarter and full year 2015 revenue and 2016 revenue outlook. Amarin plans to discuss these results and expectations for the coming year with investors in conjunction with the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, California.
JPM: 59.22 (-0.49), AMRN: 1.53 (+0.03)
Healthcare Sector Equities under the Scanner -- Zogenix, Amarin, SciClone Pharma, and PetMed Express
ACCESSWIRE - Fri Dec 18, 7:03AM CST
NEW YORK, NY / ACCESSWIRE / December 18, 2015 / Park Lane Advisor has initiated coverage on the following equities: Zogenix Inc. (NASDAQ: ZGNX), Amarin Corporation PLC (NASDAQ: AMRN), SciClone Pharmaceuticals Inc. (NASDAQ: SCLN), and PetMed Express Inc. (NASDAQ: PETS). Free research report on Zogenix can be accessed at http://www.parklaneadvisor.com/ On Thursday, December 17, 2015, the NASDAQ Composite ended at 5,002.55, down 1.35%, the Dow Jones Industrial Average declined 1.43%, to finish the day at 17,495.84, and the S&P 500 closed at 2,041.89, down 1.50%. The losses were broad based as eight out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
PETS: 17.91 (-0.03), ZGNX: 9.24 (-0.07), AMRN: 1.53 (+0.03), SCLN: 11.00 (+1.33)
Amarin Added to NASDAQ Biotechnology Index
Marketwire Canada - Mon Dec 14, 5:06AM CST
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced that it has been selected for addition to the NASDAQ Biotechnology Index effective December 21, 2015.
AMRN: 1.53 (+0.03)
Market Data on Movers and Shakers - Research on Medifast, Potbelly, Amarin and Idera Pharmaceuticals
ACCESSWIRE - Fri Dec 04, 8:00AM CST
NEW YORK, NY / ACCESSWIRE / December 4, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Medifast Inc (NYSE: MED), Potbelly Corp (NASDAQ: PBPB), Amarin Corporation plc (NASDAQ: AMRN) and Idera Pharmaceuticals Inc (NASDAQ: IDRA). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
IDRA: 1.98 (+0.05), MED: 30.19 (+0.21), AMRN: 1.53 (+0.03), PBPB: 13.61 (-0.12)
Amarin to Present at the Oppenheimer & Co. Inc. 26th Annual Healthcare Conference
Marketwired - Wed Dec 02, 5:01AM CST
Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's President and Chief Executive Officer, is scheduled to present a general company update at the Oppenheimer & Co. Inc. 26th Annual Healthcare Conference in New York City on Wednesday, December 9, 2015, at 9:10 a.m. ET.
AMRN: 1.53 (+0.03)
